Article
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
The Lancet. Infectious diseases - 1 May 2013
Lawitz Eric, Lalezari Jay P, Hassanein Tarek, Kowdley Kris V, Poordad Fred F, Sheikh Aasim M, Afdhal Nezam H, Bernstein David E, Dejesus Edwin, Freilich Bradley, Nelson David R, Dieterich Douglas T, Jacobson Ira M, Jensen Donald, Abrams Gary A, Darling Jama M, Rodriguez-Torres Maribel, Reddy K Rajender, Sulkowski Mark S, Bzowej Natalie H, Hyland Robert H, Mo Hongmei, Lin Ming, Mader Michael, Hindes Robert, Albanis Efsevia, Symonds William T, Berrey Michelle M, Muir Andrew
Abstract excerpt
BACKGROUND: Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug interactions, and side-effects restrict their use. We assessed the safety and efficacy of sofosbuvir, a uridine nucleotide analogue, in treatment-naive patients with genotype 1-3 HCV infection. METHODS: In this two-cohort, phase 2 trial, we recruited treatment-naive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.